Renal Failure News and Research

RSS

Renal failure or kidney failure is where the kidneys fail to function adequately. Renal failure is divided in acute and chronic forms; either form may be due to a large number of other medical problems.

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.

23 Apr 2013

Good news: Public support increasing for living, deceased organ donation

Good news for anyone needing a transplant; a new Mayo Clinic survey shows that the public's support for both living and deceased organ donation is increasing.

19 Apr 2013

Bioengineered kidneys transplanted into living rats produce urine

Bioengineered rat kidneys developed by Massachusetts General Hospital investigators successfully produced urine both in a laboratory apparatus and after being transplanted into living animals.

16 Apr 2013

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration has accepted for priority review the company's new drug application for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease.

15 Apr 2013

NHS intravenous (IV) fluids: an interview with Dr Ian Roberts, LSHTM

Saline is just salty water, whereas colloids are solutions that have large molecules in them. In this case, the molecules are starch. The idea is that because these molecules are big they don’t leak out of the circulation as much.

18 Mar 2013

Researchers identify enzymes that activate coronavirus for infection

Scientists all over the world are on a quest for an antidote since the first patient died from the new coronavirus in summer 2012. Infection Researchers from the German Primate Center have now identified enzymes that activate the virus for infection.

15 Mar 2013

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a study published online by JAMA.

12 Mar 2013

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia.

4 Mar 2013

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.

1 Mar 2013

Starch-based intravenous fluids cause unnecessary deaths in seriously ill patients

Starch-based intravenous (IV) fluids used by the NHS to treat seriously ill patients are causing unnecessary deaths, according to a new Cochrane systematic review by researchers at the London School of Hygiene & Tropical Medicine.

28 Feb 2013

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human].

21 Feb 2013

Hydroxyethyl starch associated with increased risk of death and acute kidney injury

In an analysis of studies that examined critically ill patients requiring an increase in blood fluid volume, intravenous use of the fluid hydroxyethyl starch was not associated with decreased mortality, according to an article appearing in the February 20 issue of JAMA.

21 Feb 2013

Misconduct biased fluid resuscitation studies

There are “serious safety concerns” associated with the use of hydroxyethyl starch for fluid resuscitation in critically ill patients, say the authors of a meta-analysis in JAMA.

20 Feb 2013

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.

16 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Chem-Aqua, Nephros partner to distribute new ultrafilters in North America

Nephros, Inc. and Chem-Aqua, Inc., a wholly owned water treatment subsidiary of NCH Corporation, announced today that the companies have signed a non-exclusive distributor agreement for Chem-Aqua to distribute Nephros's innovative ultrafilters in North America.

4 Feb 2013

Dual renin angiotensin system blockade: too many cons

Any benefit of dual blockade of the renin angiotensin system is limited to its effects on surrogate endpoints, and outweighed by an excessive risk for adverse events such as hypotension, hyperkalemia, and renal failure, argue hypertension experts.

31 Jan 2013

CKD may raise risk of mortality and end stage renal disease for both men and women

A new study from the Johns Hopkins Bloomberg School of Public Health and the Chronic Kidney Disease Prognosis Consortium (CKD-PC) found that in general chronic kidney disease is similarly associated with a higher risk of death and end stage renal disease for both women and men. The findings were released online in advance of publication in BMJ.

31 Jan 2013

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease.

23 Jan 2013

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Amgen today announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.

17 Jan 2013